Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | TLR4 | O00206 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14519187 | 1.00 | ALDH1A1 (0.50) | ALDH1A1KDM4EATMCA1CA2 | |
| SCHEMBL25444128 | 1.00 | ALDH1A1 (0.50) | ALDH1A1KDM4EATMCA1CA2 | |
| SCHEMBL14519179 | 1.00 | ALDH1A1 (0.50) | ALDH1A1KDM4EATMCA1CA2 | |
| SCHEMBL23259954 | 1.00 | ALDH1A1 (0.50) | ALDH1A1KDM4EATMCA1CA2 | |
| SCHEMBL25444531 | 0.90 | ATM (0.46) | ALDH1A1KDM4EATMCA1CA2 | |
| SCHEMBL26781677 | 0.85 | BTK (0.39) | ALDH1A1KDM4EATMEPHX1BTK | |
| SCHEMBL21161443 | 0.84 | ATM (0.50) | ALDH1A1KDM4EATMCA1CA2 | |
| SCHEMBL10217397 | 0.84 | ATM (0.50) | ALDH1A1KDM4EATMCA1CA2 | |
| SCHEMBL7894278 | 0.84 | ATM (0.50) | ALDH1A1KDM4EATMCA1CA2 | |
| SCHEMBL283828 | 0.83 | ALDH1A1 (0.61) | ALDH1A1KDM4EATMCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348518-A1 | HELICASE INHIBITORS FOR TREATMENT OF MEDICAL DISORDERS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230242543-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED | 2023-08-03 | — | — | US | disclosed |
| US-20230242543-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED | 2023-08-03 | — | — | US | disclosed |
| US-11673893-B2 | CDK inhibitors and their use as pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673893-B2 | CDK inhibitors and their use as pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230144528-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2023-05-11 | — | — | US | disclosed |
| US-20230144528-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2023-05-11 | — | — | US | disclosed |
| US-20210070761-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED | 2021-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11673893-B2 | CDK inhibitors and their use as pharmaceuticals | CDK6, CDK3, CDK9 | ALDH1A1 4032/4885KDM4E 284/4885ATM 233/4885 |
| US-20230144528-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK3, CDK9 | ALDH1A1 4032/4885KDM4E 284/4885ATM 233/4885 |
| US-20230348518-A1 | HELICASE INHIBITORS FOR TREATMENT OF MEDICAL DISORDERS | RECQL, DDX21, DDX41 | ALDH1A1 3786/4885KDM4E 1558/4885ATM 923/4885 |
| US-20230242543-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK3, CDK9 | ALDH1A1 4032/4885KDM4E 284/4885ATM 233/4885 |
| US-20210070761-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | CDK6, CDK3, CDK9 | ALDH1A1 4032/4885KDM4E 284/4885ATM 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.